Switching Australian patients with moderate to severe inflammatory bowel disease from originator to biosimilar infliximab

David Lim, Rhiannon Bandiera and Elizabeth Handsley
Med J Aust 2021; 215 (9): . || doi: 10.5694/mja2.51295
Published online: 1 November 2021

To the Editor: The SAME study affirmed the safety and efficacy of switching between originator and biosimilars and the potential for cost savings.1 Yet the global uptake of biosimilars has been relatively slow2 due to a number of factors, including marketing suggesting that such drugs are less safe or efficacious than the originator.3 Implicated in such marketing is confusion arising from the use of the word “interchangeable”, which is a defined term under United States legislation. The word “substitution” is used in Australia, which raises the likelihood of further confusion.

  • 1 Western Sydney University, Sydney, NSW
  • 2 Flinders University, Adelaide, SA
  • 3 Maynooth University, Maynooth, Ireland

Competing interests:

No relevant disclosures.


remove_circle_outline Delete Author
add_circle_outline Add Author

Do you have any competing interests to declare? *

I/we agree to assign copyright to the Medical Journal of Australia and agree to the Conditions of publication *
I/we agree to the Terms of use of the Medical Journal of Australia *
Email me when people comment on this article

Online responses are no longer available. Please refer to our instructions for authors page for more information.